long-term effects of glp-1 receptor agonists Mapping the effectiveness and risks Science Behind GLP 1 GIP
Description
Although GIP and its experimental analogs seem to have a glucagon-elevating effect, its end-action on metabolic parameters, especially when GLP-1 is present, is neutral or tilted towards benefit
T., Yao, W
Meiser J, Weindl D, Hiller K
They also reduce cardiovascular disease risk, as seen with semaglutide and liraglutide
Further reinforcing this early and rapid inflammation reduction is that a lab measure called hsCRP, or high sensitivity C-reactive protein, was significantly reduced at 4 weeks as well, when patients had only lost 2.7% of their body weight
